NCT00159913已完成3 期
A Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Parallel Group Study of Oral Sildenafil in the Treatment of Children, Aged 1-17 Years, With Pulmonary Arterial Hypertension.
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.1 个研究点 分布在 1 个国家目标入组 235 人开始时间: 2003年8月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 235
- 试验地点
- 1
- 主要终点
- Percent Change From Baseline in Peak Volume of Oxygen (VO2) Consumed : Intent To Treat Population
研究概览
简要总结
This is a clinical research study designed to evaluate sildenafil for the treatment of Pulmonary Arterial Hypertension in children, aged 1 to 17 years. The purpose of the study is to assess the efficacy, safety, and pharmacokinetics of 16 weeks of chronic treatment with oral sildenafil given in three different doses, compared to placebo (inactive treatment). Efficacy will be measured by exercise and hemodynamics. Patients who complete this trial may be eligible to take part in an extension study, in which all patients will receive active treatment of sildenafil.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 1 Year 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female subjects aged from 1 to 17 years old and weighing >= 8 kg with a mean pulmonary artery pressure >= 25 mmHg at rest, PCWP <= 15 mmHg, and PVRI >= 3 Wood units x m2 (if PCWP is not available, then mean LA pressure <= 15 mmHg or LVEDP <= 15 mmHg in the absence of left atrial obstruction).
- •Females of child bearing potential who were sexually active must have been practicing a suitable method of birth control so that in the opinion of the investigator, they would not become pregnant during the study.
- •Subjects who have symptomatic pulmonary arterial hypertension due to: primary pulmonary hypertension; pulmonary arterial hypertension in the presence of a small or hemodynamically insignificant congenital systemic to pulmonary shunt lesion that in the opinion of the investigator is not the cause of pulmonary hypertension; collagen vascular disease; congenital systemic-to-pulmonary shunts with a baseline resting room air oxygen saturation >= 88% unrepaired or repaired at least 6 months prior to screening; d-transposition of the great arteries repaired within the first 30 days of life; or surgical repair of other congenital heart lesions at least 6 months prior to screening and do not have clinically significant residual left-sided heart disease consistent with the exclusion criteria.
- •Subjects, developmentally able to exercise, whose CPX exercise test functional capacity is within the following parameters: Peak VO2 >= 10 mL/kg/min and <= 28 mL/kg/min during screening CPX test;
- •Written informed consent and assent where applicable before the subject is screened for the study.
- •Subjects who undergo a large shift in altitude (defined as approximately 5000 feet or 1524 meters) in order to participate in the study must reside at the "in study" altitude for at least 90 days prior to baseline and during the study period.
排除标准
- •Subjects with pulmonary hypertension secondary to sickle cell disease, any other disease known to be associated with PAH, or any etiology other than those specified in the inclusion criteria.
- •Left-sided heart disease, including aortic or mitral valve disease (greater than mild), restrictive or congestive cardiomyopathy; PCWP or LVEDP > 15 mmHg; LVEF < 40% determined by MUGA, angiography or echocardiography; LV shortening fraction < 22% determined by echocardiography, symptomatic coronary disease (demonstrable ischemia).
- •Pericardial constriction; significant (2+ for regurgitation) valvular disease other than tricuspid or pulmonary regurgitation; acutely decompensated heart failure within previous 30 days from screening; atrial septostomy within previous 6 months of screening;
- •Hemodynamic instability or hypo- or hypertension at screening, i.e., SBP outside of 70-140 mmHg.
- •A history of stroke, myocardial infarction or life threatening arrhythmia within 6 months of screening.
- •Moderate to severe restrictive pulmonary disease (Total Lung Capacity or Forced Vital Capacity <= 60% of normal) or history of severe lung disease.
- •Subjects with bronchopulmonary dysplasia (BPD) and other chronic lung diseases.
- •History of pulmonary embolism.
- •Subjects whose CPX test is limited by conditions other than pulmonary hypertension-associated dyspnea or fatigue.
- •Subjects who are known to be HIV positive
- •Subjects with impairment of renal function (serum creatinine > 2.5x ULN ) or hepatic function (ALT and/or AST > 3x ULN; and/or bilirubin >= 2 mg/dL). Hematological abnormalities (e.g., severe anemia, Hgb < 10 g/dL, leukopenia, WBC < 2500/mL).
- •Subjects who previously received bosentan and whose liver function tests taken at screening are > 2x ULN.
- •Subjects with any medical condition which in the opinion of the investigator may interfere with treatment, evaluation of safety, and/or efficacy.
- •Change in class of medication for CHF or PAH within the 10 days prior to qualifying right heart catheterization.
- •Subjects who are currently prescribed and/or taking nitrates or nitric oxide donors in any form. Acute vasodilator testing with nitric oxide is permitted during hemodynamic evaluation; taking chronic arginine supplementation including Heart Bar; therapy involving parenteral inotropic medication or parenteral vasodilators within 3 months of screening; current therapy with alpha-blockers, potent cytochrome P450 3A4 inhibitors (e.g., erythromycin, ketoconazole, itraconazole and protease inhibitors), Ritonavir or Nicorandil; chronic treatment with off-label sildenafil, an endothelin antagonist or prostacyclin/prostacyclin analogue within 30 days of randomization.
- •Pregnant or lactating female.
- •Any medical or psychological condition or social circumstances that would impair their ability to participate reliably in the study or who were not likely to complete the study for any reason; current or past illicit drug use or alcoholism excepting if abstinence can be documented for >= 1 year.
- •Participation in another clinical trial of an investigational drug or device (including placebo) within 30 days of screening for entry into the present study.
- •Subjects with known hereditary degenerative retinal disorders (such as retinitis pigmentosa) or history of non-arteritic anterior ischemic optic neuropathy (NAION).
研究组 & 干预措施
Sildenafil Medium dose
Experimental
干预措施: Sildenafil citrate (Drug)
Sildenafil Low dose
Experimental
干预措施: Sildenafil citrate (Drug)
Sildenafil High dose
Experimental
干预措施: Sildenafil citrate (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Percent Change From Baseline in Peak Volume of Oxygen (VO2) Consumed : Intent To Treat Population
时间窗: Baseline, Week 16
Peak VO2 (normalized for body weight) at trough plasma levels assessed by CPX testing (bicycle ergometry)at the end of treatment (Week 16 for those who completed the study). Mean Percent change = \[(week 16 value minus baseline mean)/mean at baseline\]\*100%.
Percent Change From Baseline in Peak Volume of Oxygen (VO2) Consumed : Per Protocol Population
时间窗: Baseline, Week 16
Peak VO2 (normalized for body weight) at trough plasma levels assessed by CPX testing (bicycle ergometry)at the end of treatment (Week 16 for those who completed the study). Mean Percent change = \[(week 16 value minus baseline mean)/mean at baseline\]\*100%.
次要结局
- Change From Baseline to Week 16 in Mean Pulmonary Artery Pressure (mPAP)(Baseline, Week 16)
- Change From Baseline to Week 16 in Pulmonary Vascular Resistance Index (PVRI)(Baseline, Week 16)
- Percent Change From Baseline to Week 16 in: Respiratory Exchange Ratio (RER)(Baseline, Week 16)
- Percent Change From Baseline to Week 16 in Time to Maximum Volume of Oxygen Consumed (VO2)(Baseline, Week 16)
- Change From Baseline to Week 16 in Pulmonary Vascular Resistance (PVR)(Baseline, Week 16)
- Change From Baseline to Week 16 in Cardiac Index (CI)(Baseline, Week 16)
- Change From Baseline to Week 16 in Right Atrial Pressure (RAP)(Baseline, Week 16)
- Change From Baseline to Week 16 in Child Health Questionnaire Parent Form (CHQ-PF28), Physical Scale(Baseline, Week 16)
- Change From Baseline to Week 16 in Child Health Questionnaire Parent Form (CHQ-PF28), Psychosocial Scales(Baseline, Week 16)
- Change From Baseline to Week 16 in World Health Organization (WHO) Pulmonary Hypertension (PH) Functional Class(Baseline, Week 16)
研究者
研究点 (1)
Loading locations...
相似试验
撤回
2 期
Efficacy of Sildenafil in Preterm PreeclampsiaPreterm PreeclampsiaNCT02782559The University of Texas Health Science Center, Houston
已完成
4 期
Study of Sildenafil for Treatment of SSRI-Antidepressant Sexual Dysfunction in WomenDepressionSexual DysfunctionNCT00375297University of New Mexico100
已完成
2 期
Sildenafil for Chronic Obstructive Pulmonary DiseasePulmonary Disease, Chronic ObstructiveEmphysemaNCT00104637Kawut, Steven, MD10
已完成
4 期
Study of Vardenafil in Patients Suffering From Erectile Dysfunction and Metabolic SyndromeMetabolic SyndromeErectile DysfunctionNCT00738400Bayer150
撤回
3 期
Therapeutic Effect of Sildenafil in Patients With Coronary VasospasmCoronary VasospasmNCT00454714Udo Sechtem